Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Hypertrophic cardiomyopathy (HCM) is characterized by asymmetric left ventricular hypertrophy, diastolic dysfunction and myocardial disarray. HCM is caused by mutations in sarcomeric genes, but in >40% of patients, the mutation is not yet identified. We hypothesized that FHL1, encoding four-and-a-half-LIM domains 1, could be another disease gene since it has been shown to cause distinct myopathies, sometimes associated with cardiomyopathy. We evaluated 121 HCM patients, devoid of a mutation in known disease genes. We identified three novel variants in FHL1 (c.134delA/K45Sfs, c.459C>A/C153X and c.827G>C/C276S). Whereas the c.459C>A variant was associated with muscle weakness in some patients, the c.134delA and c.827G>C variants were associated with isolated HCM. Gene transfer of the latter variants in C2C12 myoblasts and cardiac myocytes revealed reduced levels of FHL1 mutant proteins, which could be rescued by proteasome inhibition. Contractility measurements after adeno-associated virus transduction in rat-engineered heart tissue (EHT) showed: (i) higher and lower forces of contraction with K45Sfs and C276S, respectively, and (ii) prolonged contraction and relaxation with both mutants. All mutants except one activated the fetal hypertrophic gene program in EHT. In conclusion, this study provides evidence for FHL1 to be a novel gene for isolated HCM. These data, together with previous findings of proteasome impairment in HCM, suggest that FHL1 mutant proteins may act as poison peptides, leading to hypertrophy, diastolic dysfunction and/or altered contractility, all features of HCM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a drug screening platform based on engineered heart tissue
Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwörer, A., Uebeler, J., & Eschenhagen, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.211458 · Cited by 510
Self-citationHuman engineered heart tissue as a versatile tool in basic research and preclinical toxicology
Schaaf, S., Shibamiya, A., Mewe, M., Eder, A., Stöhr, A., Hirt, M. N., Rau, T., Zimmermann, W.-H., Conradi, L., Eschenhagen, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026397 · Cited by 365 · cited 1×
“Contraction measurements were performed on days 7, 9, 12, 14 and 15, as described previously (62,63).”
MethodSelf-citationvan Dijk, S. J., Paalberends, E. R., Najafi, A., Michels, M., Sadayappan, S., Carrier, L., Boontje, N. M., Kuster, D. W. D., van Slegtenhorst, M., Dooijes, D., et al. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.963702 · Cited by 124 · cited 1×
“FHL1 interacts with the C10 domain of the sarcomeric protein MyBP-C via the LIM2 domain (8), and FHL1 deficiency could alter the stability of cMyBP-C, which is also mutated in human HCM (24,43,44).”
BackgroundSelf-citation
Cited by
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Self-citationHypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
Cardiac Tissue Engineering: State of the Art
Hirt, M. N., Hansen, A., & Eschenhagen, T. (2014) · Circulation Research · doi:10.1161/circresaha.114.300522 · Cited by 425
Self-citation2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0212 · Cited by 341
Self-citationMolecular Genetic Basis of Hypertrophic Cardiomyopathy
Marian, A. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318346 · Cited by 250
Human engineered heart tissue as a model system for drug testing
Eder, A., Vollert, I., Hansen, A., & Eschenhagen, T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.010 · Cited by 190
Self-citationMybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice
Mearini, G., Stimpel, D., Geertz, B., Weinberger, F., Krämer, E., Schlossarek, S., Mourot-Filiatre, J., Stoehr, A., Dutsch, A., Wijnker, P. J. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6515 · Cited by 172
Self-citation
Metadata
- Authors
- Friedrich, F. W., Wilding, B. R., Reischmann, S., Crocini, C., Lang, P., Charron, P., Müller, O. J., McGrath, M. J., Vollert, I., Hansen, A., Linke, W. A., Hengstenberg, C., Bonne, G., Morner, S., Wichter, T., Madeira, H., Arbustini, E., Eschenhagen, T., Mitchell, C. A., Isnard, R., & Carrier, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-20
- Volume
- 21
- Issue
- 14
- Pages
- 3237-3254
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2113002155
- Cited by
- 119
- References
- 3
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.